2019
Cost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger: An Agent-Based Transmission Modeling Study
Arifin SMN, Zimmer C, Trotter C, Colombini A, Sidikou F, LaForce FM, Cohen T, Yaesoubi R. Cost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger: An Agent-Based Transmission Modeling Study. Medical Decision Making 2019, 39: 553-567. PMID: 31268405, PMCID: PMC6786941, DOI: 10.1177/0272989x19859899.Peer-Reviewed Original ResearchConceptsReactive campaignsSerogroup replacementConjugate vaccineOne-time catchPolyvalent meningococcal vaccineRoutine infant vaccinationMeningococcal conjugate vaccineMeningococcal polysaccharide vaccineRoutine infant immunizationCurrent vaccination practicesImportant health benefitsCost-effectiveness thresholdStandard cost-effectiveness thresholdsAgent-based transmission modelVaccination seriesImmunization seriesInfant vaccinationInfant immunizationPolysaccharide vaccineMeningococcal vaccineVaccination practicesPolyvalent vaccineLaboratory confirmationMenAfriVacSerogroups A
2018
Prospects for Tuberculosis Elimination in the United States: Results of a Transmission Dynamic Model
Menzies NA, Cohen T, Hill AN, Yaesoubi R, Galer K, Wolf E, Marks SM, Salomon JA. Prospects for Tuberculosis Elimination in the United States: Results of a Transmission Dynamic Model. American Journal Of Epidemiology 2018, 187: 2011-2020. PMID: 29762657, PMCID: PMC6119121, DOI: 10.1093/aje/kwy094.Peer-Reviewed Original ResearchConceptsTB preventionTB eliminationLatent TB infection (LTBI) screeningTB case detectionHigh-risk populationImportant health benefitsTransmission dynamic modelIncident TBActive TBTuberculosis eliminationInfection testingTB controlTB incidenceEpidemiologic evidenceTB transmissionInfection screeningCase detectionTuberculosis trendsUS populationRisk determinantsHealth benefitsTreatment qualityUnited StatesTreatment activitiesTreatment